News Novartis reveals more data behind Pluvicto expansion bid Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.
Oncology Radiopharmaceutical development is accelerating. Preclinical... Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
Market Access Five Takeaways from JP Morgan Week 2026 JP Morgan Week may not have produced megadeals this year, but it still yielded plenty of food for thought. Here's five quick insights from San Fran.
Oncology Radiopharmaceutical innovation: Giving cancer drugs second c... Molecular recycling could transform the economics and innovation of oncology drug discovery.
Oncology ESMO25: On radiopharmaceutical possibilities in oncology, wi... At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.
Oncology ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
